Merger-and-acquisition activity during the first quarter of 2024 was not likely to match the bustling pace of Q4 2023, when the aggregate dollar amount committed to acquisitions topped $52bn and nearly tripled the spend recorded during the previous quarter, but the first quarter did see strong M&A activity, with more than $36bn in total spend. Seven biopharma acquisitions valued at more than $1bn up front were recorded during Q1, including one above the $10bn mark.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?